168 related articles for article (PubMed ID: 32445029)
1. Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor.
Suteau V; Collin A; Menei P; Rodien P; Rousselet MC; Briet C
Cancer Immunol Immunother; 2020 Oct; 69(10):2053-2061. PubMed ID: 32445029
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature.
Guleria P; Kumar S; Malik PS; Jain D
Pathol Oncol Res; 2020 Oct; 26(4):2363-2370. PubMed ID: 32506394
[TBL] [Abstract][Full Text] [Related]
3. The expression profile of PD-L1 and CD8
Wang PF; Wang TJ; Yang YK; Yao K; Li Z; Li YM; Yan CX
J Neurooncol; 2018 Aug; 139(1):89-95. PubMed ID: 29680903
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.
Mei Y; Bi WL; Greenwald NF; Du Z; Agar NY; Kaiser UB; Woodmansee WW; Reardon DA; Freeman GJ; Fecci PE; Laws ER; Santagata S; Dunn GP; Dunn IF
Oncotarget; 2016 Nov; 7(47):76565-76576. PubMed ID: 27655724
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression in neuroendocrine tumors of the lung.
Tsuruoka K; Horinouchi H; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Asakura K; Nakagawa K; Sakurai H; Watanabe SI; Tsuta K; Ohe Y
Lung Cancer; 2017 Jun; 108():115-120. PubMed ID: 28625622
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours.
Turchini J; Sioson L; Clarkson A; Sheen A; Gill AJ
Endocr Pathol; 2021 Sep; 32(3):408-414. PubMed ID: 33694064
[TBL] [Abstract][Full Text] [Related]
7. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Significance of PD-L1/PD-1 Expression in Gastroenteropancreatic Neuroendocrine Neoplasia.
Wang C; Yu J; Fan Y; Ma K; Ning J; Hu Y; Niu W; Dong X; Wu Y; Li E; Dong D
Ann Clin Lab Sci; 2019 Sep; 49(4):448-456. PubMed ID: 31471333
[TBL] [Abstract][Full Text] [Related]
9. Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation.
von Hardenberg J; Hartmann S; Nitschke K; Worst TS; Ting S; Reis H; Nuhn P; Weis CA; Erben P
Clin Genitourin Cancer; 2019 Apr; 17(2):145-153.e5. PubMed ID: 30709785
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma.
de Vicente JC; Rodríguez-Santamarta T; Rodrigo JP; Blanco-Lorenzo V; Allonca E; García-Pedrero JM
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):546-554. PubMed ID: 30487133
[TBL] [Abstract][Full Text] [Related]
11. Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.
Inamura K; Yokouchi Y; Kobayashi M; Ninomiya H; Sakakibara R; Nishio M; Okumura S; Ishikawa Y
Cancer Med; 2017 Oct; 6(10):2347-2356. PubMed ID: 28925087
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas.
Cossu G; La Rosa S; Brouland JP; Pitteloud N; Harel E; Santoni F; Brunner M; Daniel RT; Messerer M
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760441
[TBL] [Abstract][Full Text] [Related]
14. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
15. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.
Gani F; Nagarajan N; Kim Y; Zhu Q; Luan L; Bhaijjee F; Anders RA; Pawlik TM
Ann Surg Oncol; 2016 Aug; 23(8):2610-7. PubMed ID: 27012989
[TBL] [Abstract][Full Text] [Related]
16. Expression and Prognostic Value of B7 Family Immune Checkpoints in Pancreatic Neuroendocrine Tumors.
Mo S; Zong L; Chen X; Ban X; Li M; Lu Z; Yu S; Chen J
Arch Pathol Lab Med; 2023 Feb; 147(2):193-201. PubMed ID: 35671167
[TBL] [Abstract][Full Text] [Related]
17. Programmed Death Ligand 1 (PD-L1) Expression in Epithelial Ovarian Cancer: A Comparison of Type I and Type II Tumors.
Nhokaew W; Kleebkaow P; Chaisuriya N; Kietpeerakool C
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1161-1169. PubMed ID: 31030490
[TBL] [Abstract][Full Text] [Related]
18. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K
Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407
[TBL] [Abstract][Full Text] [Related]
19. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
[TBL] [Abstract][Full Text] [Related]
20. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
